Category: Broker Research


We stress that considerations surrounding Rana Kapoor’s extension as MD & CEO of Yes Bank (YBL) is already largely in YBL stock price since (1) having to recognize upgraded divergent accounts (FY17-end) as NPA would imply only a 12.8% erosion of FY18 book value, even assuming a conservative 70% loss-given-default.
Sept. 21, 2018, 11:08 a.m.
Publisher: nirmalbang.com

We take Punjab National Bank (PNB) out from Under Review and assign an Accumulate rating since (1) growth remains an issue for the bank even though (2) asset quality issues are largely behind the bank.
Sept. 19, 2018, 11:12 a.m.
Publisher: nirmalbang.com

The USFDA conducted an inspection at SUNP’s Mohali plant during 10-14 September 2018, and issued Form 483 with two observations.
Sept. 19, 2018, 11:04 a.m.
Publisher: motilaloswal.com

The stock has been fuelled by outstanding Q1 numbers. Microfinance in today's world has great potential and is possibly one of the next great innovation hub. Ujjivan could turn out to be a POWER ELITE Stock during the course of time.
Sept. 18, 2018, 11:17 p.m.


The demand for medium and heavy commercial vehicles (MHCVs) has remained strong after the government’s announcement of new axle load norms in July 2018.
Sept. 18, 2018, 11:29 a.m.
Publisher: nirmalbang.com

Another major step as part of ongoing banking reforms; to pave way for further consolidation! In yet another unexpected move, the Indian government announced the amalgamation of three public sector lenders – Bank of Baroda, Dena Bank and Vijaya Bank.
Sept. 18, 2018, 11:26 a.m.
Publisher: motilaloswal.com

Piramal Enterprises Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 53,501.22 crores. The stock has been reporting good set of numbers since the last few quarters.
Sept. 18, 2018, 11:10 a.m.
Publisher: edelweiss.in

Operational performance at GFL has improved robustly with EBITDA margins at 28.2% in FY18 (21.0% in FY17) resulting in RoCE rising to 13.1% in FY18 (8.2% in FY17).
Sept. 17, 2018, 12:17 p.m.
Author : Way2wealth | Publisher: indianotes.com

In our view, experienced management team, strong profitability trends, improving return profile coupled with change in business mix more towards retail – all these factors put together would drive re-rating in the stock.
Sept. 17, 2018, 11:53 a.m.
Author : LKP Securities | Publisher: indianotes.com

Sun Pharmaceutical Industries (SPIL) has received the US Food and Drug Administration or USFDA’s approval for Xelpros - a novel drug formulation of Xalatan (latanoprost) - the most widely prescribed treatment for Glaucoma.
Sept. 17, 2018, 11:29 a.m.
Publisher: nirmalbang.com